Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
暂无分享,去创建一个
Hong Wu | George Thomas | Ingo K. Mellinghoff | I. Mellinghoff | C. Sawyers | B. Stiles | Hong Wu | G. Thomas | J. Gibbons | M. Neshat | C. Tran | Roseann Petersen | P. Frost | Charles L. Sawyers | Chris Tran | Bangyan Stiles | Mehran S. Neshat | Roseann Petersen | Philip Frost | James J. Gibbons
[1] A. Gingras,et al. Regulation of translation initiation by FRAP/mTOR. , 2001, Genes & development.
[2] P. Vogt,et al. A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[3] R. Burcelin,et al. Hypoinsulinaemia, glucose intolerance and diminished β-cell size in S6K1-deficient mice , 2000, Nature.
[4] T. P. Neufeld,et al. Regulation of cellular growth by the Drosophila target of rapamycin dTOR. , 2000, Genes & development.
[5] E. Hafen,et al. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. , 2000, Genes & development.
[6] Tobias Schmelzle,et al. TOR, a Central Controller of Cell Growth , 2000, Cell.
[7] C. Sherr. The Pezcoller lecture: cancer cell cycles revisited. , 2000, Cancer research.
[8] Christine C. Hudson,et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. , 2000, Cancer research.
[9] Chen-Yang Shen,et al. PIK3CA as an oncogene in cervical cancer , 2000, Oncogene.
[10] T. P. Neufeld,et al. Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways. , 2000, Developmental biology.
[11] D. Goberdhan,et al. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. , 1999, Genes & development.
[12] E. Hafen,et al. PTEN affects cell size, cell proliferation and apoptosis during Drosophila eye development. , 1999, Development.
[13] L. Schriml,et al. Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity. , 1999, Journal of the National Cancer Institute.
[14] A. Belldegrun,et al. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. , 1999, Cancer research.
[15] E. Hafen,et al. Drosophila S6 kinase: a regulator of cell size. , 1999, Science.
[16] W. Liu,et al. Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.
[17] Brian A. Hemmings,et al. Protein Kinase B Localization and Activation Differentially Affect S6 Kinase 1 Activity and Eukaryotic Translation Initiation Factor 4E-Binding Protein 1 Phosphorylation , 1999, Molecular and Cellular Biology.
[18] H. Wu,et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[19] L. Cantley,et al. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[20] C. Sawyers,et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[21] M. Roussel,et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.
[22] N. Rosen,et al. Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway* , 1998, The Journal of Biological Chemistry.
[23] P. Houghton,et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. , 1998, Molecular pharmacology.
[24] J. Avruch,et al. Amino Acid Sufficiency and mTOR Regulate p70 S6 Kinase and eIF-4E BP1 through a Common Effector Mechanism* , 1998, The Journal of Biological Chemistry.
[25] R. Vessella,et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] E. Gelfand,et al. Targeted disruption of p70(s6k) defines its role in protein synthesis and rapamycin sensitivity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[27] A. Gingras,et al. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. , 1998, Genes & development.
[28] W. Cavenee,et al. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[29] C. Eng,et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.
[30] Jing Li,et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.
[31] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[32] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[33] R. Abraham,et al. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3‐kinase inhibitors, wortmannin and LY294002. , 1996, The EMBO journal.
[34] S. Schreiber,et al. A Signaling Pathway to Translational Control , 1996, Cell.
[35] A. Gingras,et al. 4E-BP1 phosphorylation is mediated by the FRAP-p70s6k pathway and is independent of mitogen-activated protein kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[36] J. Cheng,et al. Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[37] A. Gingras,et al. Rapamycin blocks the phosphorylation of 4E‐BP1 and inhibits cap‐dependent initiation of translation. , 1996, The EMBO journal.
[38] S. Schreiber,et al. PIK-Related Kinases: DNA Repair, Recombination, and Cell Cycle Checkpoints , 1995, Science.
[39] S. Schreiber,et al. Control of p70 S6 kinase by kinase activity of FRAP in vivo , 1995, Nature.
[40] N. Sonenberg,et al. Eukaryotic Translation Initiation Factor 4E Regulates Expression of Cyclin D1 at Transcriptional and Post-transcriptional Levels (*) , 1995, The Journal of Biological Chemistry.
[41] R. Abraham,et al. Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells (*) , 1995, The Journal of Biological Chemistry.
[42] V. Berlin,et al. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[43] A. Nairn,et al. Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[44] Paul Tempst,et al. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs , 1994, Cell.
[45] Stuart L. Schreiber,et al. A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.
[46] G. Thomas,et al. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[47] P. Houghton,et al. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. , 1994, Cancer research.
[48] J. Cheng,et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[49] G. Crabtree,et al. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase , 1992, Nature.
[50] S. Schreiber,et al. Chemistry and biology of the immunophilins and their immunosuppressive ligands. , 1991, Science.